Advertisement

Neurological Sciences

, Volume 29, Supplement 1, pp 110–122 | Cite as

Acute and prophylactic treatments for migraine: present and future

  • Alan M. RapoportEmail author
Key Note Lecture

Abstract

Herein I will present general principles of acute-care and preventive therapy of migraine, both in the present and the future. Details of currently used migraine acute-care therapies with their contraindications, drug-drug interactions and adverse events will be presented. Details of migraine preventive therapies with their adverse events and drug-drug interactions will be discussed. Some over-the-counter vitamins, minerals and herbs, used as preventive therapy in migraine, will be discussed. Future treatments in the pipeline will be briefly detailed.

Keywords

Migraine Migraine acute therapy Migraine preventive therapy Headache treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cady RK (2001) Treatment strategies for migraine headache. JAMA 285:1014–1015PubMedCrossRefGoogle Scholar
  2. 2.
    Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine — current understanding and treatment. N Engl J Med 346:257–270PubMedCrossRefGoogle Scholar
  3. 3.
    Matchar DB, Young WB, Rosenberg JH et al (2000) Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. www.neurology.org. AprilGoogle Scholar
  4. 4.
    Mathew NT, Kailasam J, Fischer A (2001) Early intervention using rofecoxib alone, rizatriptan alone and combination of rizatriptan and rofecoxib in acute migraine. Cephalalgia 21:405–432CrossRefGoogle Scholar
  5. 5.
    Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307–314PubMedCrossRefGoogle Scholar
  6. 6.
    Krymchantowski AV, Barbosa JS (2002) Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22:309–312PubMedCrossRefGoogle Scholar
  7. 7.
    Klapper J, Stanton J (1991) The emergency treatment of acute migraine headache; a comparison of intravenous dihydroergota-mine, dexamethasone, and placebo. Cephalalgia 11[Suppl 11]:159–160Google Scholar
  8. 8.
    Rapoport AM, Tepper SJ (2001) Triptans are all different. Arch Neurol 58:1479–1480PubMedCrossRefGoogle Scholar
  9. 9.
    Longmore J, Razzaque Z, Shaw D et al (1998) Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol 46:577–582PubMedCrossRefGoogle Scholar
  10. 10.
    Kuzybski W (1992) Metamizole and hydrocortisone for the interruption of a migraine attack — preliminary study. Headache Q 3:326–328Google Scholar
  11. 11.
    Ramadan NM, Silberstein SD, Freitag FG et al (2000) Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. www.neurology.org. AprilGoogle Scholar
  12. 12.
    Weber RB, Reinmuth OM (1971) The treatment of migraine with propranolol. Neurology 21:404–405Google Scholar
  13. 13.
    Reveiz-Herault L, Cardona AF, Ospina EG, Carrillo P (2003) [Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature]. Rev Neurol 36:907–912. Review, in SpanishPubMedGoogle Scholar
  14. 14.
    Silberstein SD (2001) Migraine: preventive treatment. Curr Med Res Opin 17[Suppl 1]:s87–s93PubMedCrossRefGoogle Scholar
  15. 15.
    Tomkins GE, Jackson JL, O’Malley PG et al (2001) Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 111:54–63PubMedCrossRefGoogle Scholar
  16. 16.
    Saper JR, Silberstein SD, Lake AE et al (1995) Fluoxetine and migraine: comparison of double-blind trials. Headache 35:233PubMedCrossRefGoogle Scholar
  17. 17.
    Mathew N, Saper J, Silberstein S et al (1995) Migraine prophylaxis with divalproex. Arch Neurol 52:281–286PubMedGoogle Scholar
  18. 18.
    Edwards KR, Potter DL, Wu SC et al (2003) Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr 8:428–432PubMedGoogle Scholar
  19. 19.
    Mathew NT, Rapoport A, Saper J et al (2001) Efficacy of gabapentin in migraine prophylaxis. Headache 41:119–128PubMedCrossRefGoogle Scholar
  20. 20.
    Steiner TJ, Findley LJ, Yuen AW (1997) Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17:109–112PubMedCrossRefGoogle Scholar
  21. 21.
    D’Andrea G, Granella F, Cadaldini M, Manzoni GC (1999) Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 19:64–66PubMedCrossRefGoogle Scholar
  22. 22.
    Drake ME, Greathouse NI, Armentbright AD, Renner JB (2001) Preventive treatment of migraine with zonisamide. Cephalalgia 21:374Google Scholar
  23. 23.
    Krusz JC (2001) Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 21:373Google Scholar
  24. 24.
    Sharma S, Jacobs HS (1997) Polycystic ovary syndrome associated with treatment with the anticonvulsant sodium valproate. Curr Opin Obstet Gynecol 9:391–392PubMedGoogle Scholar
  25. 25.
    Muller R, Weller P, Chemaissani A (1991) Pleural fibrosis as a side effect of years-long methysergide therapy. Dtsch Med Wochenschr 116:1433–1436PubMedCrossRefGoogle Scholar
  26. 26.
    Peatfield R (1986) Drugs acting by modification os serotonin function. Headache 26:129–131Google Scholar
  27. 27.
    Haria M, Balfour JA (1997) Levetiracetam. CNS Drugs 7:159–164CrossRefGoogle Scholar
  28. 28.
    Bigal ME, Krymchantowski AV, Rapoport AM (2003) New developments in migraine prophylaxis. Expert Opin Pharmacother 4:433–443. ReviewPubMedCrossRefGoogle Scholar
  29. 29.
    Tronvik E, Stovner LJ, Helde G et al (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289:65–69PubMedCrossRefGoogle Scholar
  30. 30.
    Silberstein S, Mathew N, Saper J, Jenkins S (2000) Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40:445–450PubMedCrossRefGoogle Scholar
  31. 31.
    Wang SJ, Fuh JL, Lu SR et al (2003) Migraine prevalence during menopausal transition. Headache 43:470–478PubMedCrossRefGoogle Scholar
  32. 32.
    Lipton RB, Gobel H, Wilks K, Mauskop A (2002) Efficacy of petasites (an extract from petasites rhizone) 50 and 75 mg for prophylaxis of migraine: results of a randomized, double-blind, placebo-controlled study. Neurology 58[Suppl 3]:A472Google Scholar
  33. 33.
    Altura BM, Altura BT (1978) Magnesium and vascular tone and reactivity. Blood Vessels 15:5–16PubMedGoogle Scholar
  34. 34.
    Welch KM, Ramadan NM (1995) Mitochondria, magnesium and migraine. J Neurol Sci 134:9–14PubMedCrossRefGoogle Scholar
  35. 35.
    Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of highdose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50:466–470PubMedGoogle Scholar
  36. 36.
    Sandor PS, Clemente LD, Coppola G et al (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlle trial. Neurology 64:713–715PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  1. 1.The David Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.The New England Center for HeadacheStamfordUSA
  3. 3.Los AngelesUSA

Personalised recommendations